Cerus presents on pathogen-reduced components at symposium
The two-day symposium was called because of the most recent Food and Drug Administration (FDA) approvals and because of an article in the New England Journal of Medicine that urges the FDA to mandate pathogen reductions. The presentation included a number of details about the INTERCEPT Blood System and how it could impact the future of health care. Cerus’ presentation covered various methods about how to apply INTERCEPT in order to reduce pathogens and transfusion services.
One of the topics pertained to the current label on INTERCEPT that was approved by the FDA. This label shows that INTERCEPT can decrease the risk of transfusion-transmitted infections in apheresis platelet components as well as whole blood derived plasma components. INTERCEPT also provide advantages for key potential blood center operations, including reducing component waste in early platelet release and platelet availability. It also reduces pathogens.
Cerus plans to expand its claims to a seven-day platelet shelf-life extension. It also wants to develop a triple set storage INTERCEPT kit that will improve the efficiency of collecting platelets. Further plans include the capability of reducing pathogens among whole blood derived platelets.
Cerus researchers plan to continue developing red blood cell systems after completing U.S. Phase II and European Phase III trials.